iCardiac Technologies’ COMPAS Technology Validated in Peer Reviewed Publication Co-Authored by FDA and University of Rochester

Rochester, New York – January 21, 2009 – iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development, today announced that Computers in Cardiology has published an article by authors from the University of Rochester and the FDA demonstrating the use of the Highly Automated QT technology in data analysis in Thorough QT studies. The publication concludes that the Highly Automated COMPAS technology is equivalent to the costly process of manually evaluating QT measurements in all ECGs in cardiac safety studies.